as of 03-06-2026 3:53pm EST
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.
| Founded: | 1954 | Country: | United States |
| Employees: | N/A | City: | GREENFIELD |
| Market Cap: | 10.3B | IPO Year: | 2018 |
| Target Price: | $27.63 | AVG Volume (30 days): | 4.2M |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.47 | EPS Growth: | -169.12 |
| 52 Week Low/High: | $8.02 - $27.72 | Next Earning Date: | 05-25-2026 |
| Revenue: | $4,715,000,000 | Revenue Growth: | 6.22% |
| Revenue Growth (this year): | 7.97% | Revenue Growth (next year): | 5.21% |
| P/E Ratio: | -50.82 | Index: | N/A |
| Free Cash Flow: | 284.0M | FCF Growth: | -27.92% |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Director
Avg Cost/Share
$21.30
Shares
10,000
Total Value
$213,000.00
Owned After
131,773
SEC Form 4
PRESIDENT, CEO AND DIRECTOR
Avg Cost/Share
$21.75
Shares
22,000
Total Value
$478,495.60
Owned After
167,000
SEC Form 4
SEE REMARKS
Avg Cost/Share
$21.33
Shares
4,500
Total Value
$95,985.00
Owned After
123,082
SEC Form 4
EVP and CFO
Avg Cost/Share
$21.64
Shares
6,950
Total Value
$150,426.50
Owned After
124,233
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Kurzius Lawrence Erik | ELAN | Director | Dec 12, 2025 | Buy | $21.30 | 10,000 | $213,000.00 | 131,773 | |
| Simmons Jeffrey N | ELAN | PRESIDENT, CEO AND DIRECTOR | Dec 11, 2025 | Buy | $21.75 | 22,000 | $478,495.60 | 167,000 | |
| Modi Rajeev A. | ELAN | SEE REMARKS | Dec 11, 2025 | Buy | $21.33 | 4,500 | $95,985.00 | 123,082 | |
| VanHimbergen Robert M | ELAN | EVP and CFO | Dec 11, 2025 | Buy | $21.64 | 6,950 | $150,426.50 | 124,233 |
SEC 8-K filings with transcript text
Feb 24, 2026 · 100% conf.
1D
-1.77%
$25.96
5D
-3.21%
$25.58
20D
-11.65%
$23.35
elan-20260224FALSE000173910400017391042026-02-242026-02-24
Washington, D.C. 20549
Form 8-K
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 24, 2026
Elanco Animal Health Incorporated (Exact name of Registrant as specified in its charter)
001-38661 82-5497352 (State or other jurisdiction of(Commission File (I.R.S. Employer incorporation)Number) Identification No.)
46221
(Zip Code) (Address of principal executive offices)
Registrant’s telephone number, including area code: (877) 352-6261
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common stock, no par valueELANNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ☐ Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations or Financial Condition. Attached as Exhibit 99.1 and incorporated by reference into this Item 2.02 is a copy of the press release, dated February 24, 2026, announcing the results of operations for the full year and fiscal quarter ended December 31, 2025, and guidance for the full year and first quarter of 2026, for Elanco Animal Health Incorporated. The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit NumberDescription
99.1Press Release issued by Elanco Animal Health Incorporated dated February 24, 2026
104.1Cover Page Interactive Data File (embedded within the Inline XBRL document)
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date:February 24, 2026/s/ Robert M. VanHimbergen Robert M. VanHimbergen Executive Vice President and Chief Financial Officer
Nov 5, 2025
elan-20251105FALSE000173910400017391042025-11-052025-11-05
Washington, D.C. 20549
Form 8-K
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 5, 2025
Elanco Animal Health Incorporated (Exact name of Registrant as specified in its charter)
001-38661 82-5497352 (State or other jurisdiction of(Commission File (I.R.S. Employer incorporation)Number) Identification No.)
46221
(Zip Code) (Address of principal executive offices)
Registrant’s telephone number, including area code: (877) 352-6261
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common stock, no par valueELANNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ☐ Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations or Financial Condition. Attached as Exhibit 99.1 and incorporated by reference into this Item 2.02 is a copy of the press release, dated November 5, 2025, announcing the results of operations for the fiscal quarter ended September 30, 2025, and guidance for the full year and fourth quarter of 2025, for Elanco Animal Health Incorporated. The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit NumberDescription
99.1Press Release issued by Elanco Animal Health Incorporated dated November 5, 2025
104.1Cover Page Interactive Data File (embedded within the Inline XBRL document)
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date:November 5, 2025/s/ Robert M. VanHimbergen Robert M. VanHimbergen Executive Vice President and Chief Financial Officer
Aug 7, 2025
elan-20250807FALSE000173910400017391042025-08-072025-08-07
Washington, D.C. 20549
Form 8-K
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 7, 2025
Elanco Animal Health Incorporated (Exact name of Registrant as specified in its charter)
001-38661 82-5497352 (State or other jurisdiction of(Commission File (I.R.S. Employer incorporation)Number) Identification No.)
46140
(Zip Code) (Address of principal executive offices)
Registrant’s telephone number, including area code: (877) 352-6261
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common stock, no par valueELANNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ☐ Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations or Financial Condition. Attached as Exhibit 99.1 and incorporated by reference into this Item 2.02 is a copy of the press release, dated August 7, 2025, announcing the results of operations for the fiscal quarter ended June 30, 2025, and guidance for the full year and third quarter of 2025, for Elanco Animal Health Incorporated. The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit NumberDescription
99.1Press Release issued by Elanco Animal Health Incorporated dated August 7, 2025
104.1Cover Page Interactive Data File (embedded within the Inline XBRL document)
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date:August 7, 2025/s/ Robert M. VanHimbergen Robert M. VanHimbergen Executive Vice President and Chief Financial Officer
ELAN Breaking Stock News: Dive into ELAN Ticker-Specific Updates for Smart Investing
AI Sentiment
Highly Positive
9/10
See how ELAN stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "ELAN Elanco Animal Health Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.
